Board Boost: bioAffinity’s Next-Touch Play
bioAffinity taps new board. Pipeline alert: CyPath® Lung ramp incoming. Pitch CRM & analytics to close deals. Checklist for your next touch.
Published on
Do not index
Do not index
🚀 Battle Card: bioAffinity Technologies, Inc.
Quick trigger:
👤 Decision Maker in the News
- Roberto Rios, CPA, Board of Directors Member · 🔗 LinkedIn
- John J. Oppenheimer, M.D., Board of Directors Member · 🔗 LinkedIn
💡 Why It Matters
- This bioAffinity Technologies, Inc. sales trigger signals a commercial ramp for CyPath® Lung and accelerated development of asthma/COPD companion diagnostics. → Source
🎯 Core Pain Point
- Scaling CyPath® Lung sales in a competitive diagnostics market
- Advancing companion diagnostics for asthma and COPD pipelines
💰 What to Pitch
- Primary: CRM & sales analytics platform → accelerate CyPath® Lung market penetration
- Expansion: Clinical Trial Management System → streamline companion diagnostic validation
🗺️ Quick Context
- HQ: San Antonio, TX
- Employees: 52
- Rev: ≈ $15 M
- Website: bioaffinitytech.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win **bioAffinity Technologies, Inc.*’s business.
- Salesforce — CRM / Sales Analytics
- Unique edge: End-to-end biotech sales workflows
- Evaluated by VP Sales for integration with existing labs
- Veeva CRM — Life Sciences CRM
- Unique edge: Prebuilt compliance for diagnostics
- Evaluated by Dir. Commercial Ops for regulatory fit
- HubSpot CRM — CRM / Marketing Automation
- Unique edge: Rapid deployment & low TCO
- Evaluated by Finance for budget-friendly scaling
✅ Do-Now Checklist
Connect with Roberto Rios & John J. Oppenheimer on LinkedIn
Reference this bioAffinity Technologies, Inc. sales trigger in your first email/DM
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑CRM & sales analytics platform for accelerated CyPath® Lung market penetration❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Roberto
COMPANY = bioAffinity Technologies, Inc.
DEPT = Sales
SIZE = ≈ TBD
BOTTLENECK = Scaling CyPath® Lung sales in a competitive diagnostics market
EVENT = Appoints New Board Members
DETAIL = Appoints New Members to Board of Directors
PAIN = Scaling CyPath® Lung sales in a competitive diagnostics market
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250818670799&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 52
REV_EST = ≈ TBD
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ TBD-person Sales
Roberto—noticed your Sales team is ≈ TBD.
That’s when Scaling CyPath® Lung sales in a competitive diagnostics market slows growth.
We helped ≈ TBD fix this with CRM & sales analytics platform for accelerated CyPath® Lung market penetration.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about Appoints New Members to Board of Directors — Scaling CyPath® Lung sales in a competitive diagnostics market.
CRM & sales analytics platform for accelerated CyPath® Lung market penetration. ≈ TBD.
Quick chat?